Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis

BioDrugs

Volumn 17, Issue 2, 2003, Pages 139-145

  Culy, Christine R ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; HEADACHE; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; NAUSEA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SEIZURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0037261293     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317020-00006     Document Type: Review

References (64)

1. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57 (6): 945-66
2. Davis T, Friend D, Smith CA. Comparative TNF binding characteristics of etanercept (Enhrel®) and infliximab (Remicade) [abstract no. FRI0081 and poster]. Ann Rheum Dis 2002; 61 Suppl. 1: 184
3. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993 Dec 1; 151 (11): 6602-7
4. Drynda S, Kühne C, Kekow J. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor β levels in rheumatoid arthritis. Ann Rheum Dis 2002 Mar; 61 (3): 254-6
5. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis Factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002 May; 41 (5): 484-9
6. Verschueren PC, Markusse H, Smeets TJM, et al. Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (P75) in RA patients [abstract no. 762]. Arthritis Rheum 1999 Sep; 42 (9 Suppl.): S197
7. Schotte H, Willeke P, Schorat MA, et al. Longterm treatment with etanercept significantly reduces the number of TNFα and IL-1 producing peripheral blood mononuclear cells from patients with rheumatoid arthritis [abstract no. 375]. Arthritis Rheum 2001 Sep; 44 (9 Suppl.): S115
8. Lampa J, Berg L, Rogberg S, et al. Functional effects on peripheral T-cells of treatment with soluble TNF-α receptors in rheumatoid arthritis [abstract no. POS-417]. Ann Rheum Dis 2000 Jul: 59 Suppl. 1: 163
9. Moreland LW, Bucy RP, Weinblatt ME, et al. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002 Apr; 103 (1): 13-21
10. Immunex. Enbrel® (etanercept) prescribing information [online]. Available from URL: http://www.immunex.com [Accessed 2002 Sep 13]
11. Lebsack ME, Hanna RK, Lange MA, et al. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers [abstract no. 233]. Pharmacotherapy 1997; 17 (5): 1118
12. European Agency for Evaluation of Medicinal Products. Scientific discussion: Enbrel® [online]. Available from URL: http://www.emea.eu.int [Accessed 2002 Mar 10]
13. European Agency for Evaluation of Medical Products. Enbrel®: summary of product characteristics [online]. Available from URL: http://emea.eu.int [Accessed 2002 Mar 10]
14. Soran O, Feldman AM, Schneider VM, et al. The pharmacokinetics of etanercept in patients with heart failure [letter]. Br J Clin Pharmacol 2001 Feb; 51: 191-2
15. Korth-Bradley JM, Parks V, Buckwalter ME, et al. Lack of a clinically relevant interaction between etanercept (E) and warfarin (W) [poster]. American College of Clinical Pharmacy Spring Practice and Research Forum; 2002 Apr 7-10; Savannah (GA)
16. Patat AA, Parks V, Simcoe DK, et al. Lack of a clinically relevant interaction between etanercept (E) and digoxin (D) [abstract no. 82 and poster]. Clin Pharmacol Ther 2002; 71: P64
17. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000 Nov; 343 (22): 1586-93
18. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002 Jun; 46 (6): 1443-50
19. Genovese M, Martin R, Fleischmann R, et al. Etanercept (Enbrel®) in early erosive rheumatoid arthritis (ERA trial): observations at 3 years [abstract no. 151]. Arthritis Rheum 2001 Sep; 44 (9 Suppl.): 78
20. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002 Mar; 8 (3): 231-40
21. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337 (3): 141-7
22. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999 Mar 16; 130 (6): 478-86
23. Wajdula J, on behalf of the Etanercept European Investigators Network. A double-blind, placebo-controlled study of the efficacy and safety of four different doses of etanercept in patients with rheumatoid arthritis [abstract no. POS-414]. Ann Rheum Dis 2000 Jul; 59 Suppl. 1: S163
24. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340 (4): 253-9
25. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001 Jun; 28: 1238-44
26. Baumgartner SW, Moreland LW, Cohen SB, et al. Long-term use of Enbrel® (etanercept) in patients with DMARD-refractory rheumatoid arthritis [abstract no. W114]. J Rheumatol 2001 Jul; 28 Suppl. 63: 104
27. Willis RF, Pedersen R, Etanercept European Investigators Network. A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis) [abstract no. W104]. J Rheumatol 2001 Jul; 28 Suppl. 63: 101
28. Klareskog L, Wajdula J, Pedersen R, et al. A long-term, open-label trial of the safety and efficacy of etanercept (25mg twice weekly) in patients with rheumatoid arthritis (interim analysis) [abstract no. FRI0050]. Ann Rheum Dis 2002; 61 Suppl. 1: 175
29. Moreland LW, Cohen S, Fleischmann RM, et al. Safety and efficacy of up to 5 years of etanercept (Enbrel®) therapy in rheumatoid arthritis [abstract no. FRI0078]. Ann Rheum Dis 2002; 61 Suppl. 1: 183
30. Weinblatt ME, Kremer JM, Lange M, et al. Long-term safety and efficacy of combination therapy with methotrexate and etanercept (Enbrel®) [abstract no. 1982]. Arthritis Rheum 1999 Sep; 42 (9 Suppl.): 401
31. Kremer JM, Weinblatt ME, Fleischmann RM, et al. Etanercept (Enbrel®) in addition to methotrexate in rheumatoid arthritis: long-term observations [abstract no. 152]. Arthritis Rheum 2001 Sep; 44 (9 Suppl.): 78
32. Kremer JM, Weinblatt ME, Fleischmann RM, et al. Etanercept (Enbret®) in addition to methotrexate in rheumatoid arthritis: long-term observations [abstract no. FRI0070]. Ann Rheum Dis 2002; 61 Suppl. I: 181
33. Yazici Y, Erkan D, Kulman I, et al. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world". Ann Rheum Dis 2002 Jul; 61 (7): 638-40
34. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002 Sep; 61 (9): 793-8
35. Gaebel K, Levine M, Wang E. Monitoring of health outcomes in patients using etanercept (Enbrel®) in a community setting: the Enbrel Community Health Outcomes [ECHO] Study) [abstract no. SAT0347]. Ann Rheum Dis 2002; 61 Suppl. 1: 348
36. Van Vollenhoven RF, Ernestam S, Harju A, et al. Etanercept plus MTX versus etanercept in the Stockholm TNF-alpha antagonist registry (STURE): the combination is more effective at 3 to 12 months follow-up [abstract no. FRI0112]. Ann Rheum Dis 2002; 61 Suppl. 1: 193
37. Power DJ, Yocum DE, Nordensson KA. Assessment of biologic agents use in a university rheumatology clinic [abstract no. AB0124]. Ann Rheum Dis 2002; 61 Suppl. 1: 380
38. Feltelius NJV, Lindblad S, Fored M, et al. A national drug monitoring system - TNF blocker treatment in patients with rheumatoid arthritis [abstract no. FRI0044]. Ann Rheum Dis 2002; 61 Suppl. 1: 173
39. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 Jul 29; 356: 385-90
40. Lebwohl M, Gottlieb A, Mease P, et al. Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase 3 multicentre clinical trial [abstract P561 and poster]. 60th Annual Scientific Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans (LA)
41. Wanke LA, Gottleib AB, Burge DJ, et al. Etanercept improves health-related quality of life in patients with psoriatic arthritis [abstract no. PS31 and poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans (LA)
42. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000 Mar 16; 342 (11): 763-9
43. Lovell DJ, Giannini EH, Passo M, et al. Long-term efficacy of etanercept (Enbrel®) in children with polyarticular-course juvenile rheumatoid arthritis [poster]. VII European Pediatric Rheumatology Congress; 2001 Sep; Berlin
44. Lahdenne P, Honkanen V. Infliximab vs. etanercept in the treatment of severe juvenile chronic arthritis [abstract no. 1888]. Arthritis Rheum 2000 Sep; 43 (9 Suppl.): 381
45. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002 Feb; 61 (2): 171-3
46. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002 Jun: 29 (6): 1156-65
47. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000 Oct; 43 (10): 2316-27
48. Brennan A, Bansback N, Conway P, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis (RA) in the UK [abstract no. 630]. Arthritis Rheum 2001 Sep; 44 (9 Suppl.): S157
49. Jobanputra P, Barton P, Bryan S, et al. The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab [online]. Available from URL: http://www.nice.org.uk/pdf/RA AssessmentReport.pdf [Accessed 2002 Sep 23]
50. Malone DC, Ortmeier BG. Cost efficacy of etanercept versus infliximab plus methotrexate in the treatment of DMARD-resistant rheumatoid arthritis [abstract no. SAT0320]. Ann Rheum Dis 2002; 61 Suppl. 1: 340
51. Malone DC. Cost-effectiveness analysis of etanercept monotherapy versus infliximab plus methotrexate in the treatment of rheumatoid arthritis [abstract no. 1617]. Arthritis Rheum 2001 Sep; 44 (9 Suppl.): S322
52. Nuijten MJC, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19 (10): 1051-64
53. Geborek P, Eberhardt K, Saxane T. Etanercept and infliximab treatment reduces hospital care in arthritis patients [abstract no. FRI0109]. Annual European Congress on Rheumatology; 2002 Jun 12-15; Stockholm
54. Geborek P, Eberhardt K, Larsson B, et al. Etanercept and infliximab treatment improves working capacity in arthritis patients [abstract no. FRI0038]. Annual European Congress on Rheumatology; 2002 Jun 12-15; Stockholm
55. Wajdula J, Pedersen R, Sanda M, et al. A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis) [abstract no. 974]. Arthritis Rheum 2000 Sep; 43 Suppl.: 229
56. Klareskog L, Moreland LM, Bohen SB, et al. Global safety and efficacy of up to five years of etanercept (Enbrel®) therapy [abstract no. 150]. Arthritis Rheum 2001 Sep; 44 (9 Suppl.): S77
57. Sabath DF, Holman J, Wallis WJ. Serious infection reports with etanercept (Enbrel®) therapy [abstract no. OP0099]. Ann Rheum Dis 2002; 61 (Suppl. 1): 38
58. Holman J, Wallis WJ, Sabath DF, et al. Tuberculosis reports with etanercept (Enbrel®) therapy [abstract no. FRI0024]. Ann Rheum Dis 2002; 61 Suppl. 1: 167
59. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002 Feb 16; 359 (9306): 579-80
60. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus [letter]. Rheumatology (Oxford) 2001 Nov; 40 (11): 1317-9
61. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med 1999 Oct 19; 131 (8): 634
62. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000; 27 (8): 2041-4
63. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44 (12): 2862-9
64. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001 Nov 27; 57 (10): 1885-8